Skip to main content
. Author manuscript; available in PMC: 2014 Oct 2.
Published in final edited form as: Cancer. 2009 Jun 1;115(11):2482–2490. doi: 10.1002/cncr.24257

Table 3.

Frequency of Bleeding Episodes in Patients Receiving Dasatinib Therapy According to Anatomic Location, CML Phase, and Platelet Count

No. of Bleeding
Episodes (%)
Characteristic Total
No. (%)		 CML Phase
Location CP AP BP
UGIB 8 (22) 3 (8) 2 (5) 3 (8)
LGIB 22 (59) 5 (14) 7 (19) 10 (27)
Gingival 4 (11) 1 (3) 2 (5) 1 (3)
Vaginal 2 (5) 1 (3) 1 (3) 0 (0)
Epistaxis 1 (3) 0 (0) 1 (3) 0 (0)
Platelet count (×109/L)
  <30 18 (49) 0 (0) 8 (22) 10 (27)
  30–100 5 (14) 2 (5) 0 (0) 3 (8)
  >100 14 (37) 8 (22) 5 (14) 1 (3)

CML indicates chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; BP, blastic phase; UGIB, upper gastrointestinal bleeding; LGIB, lower gastrointestinal bleeding.